Literature DB >> 21735280

[Reduced vocal cord movement and hypopharyngeal tumor].

K Jahn1, A O H Gerstner, W Hartmann, G Schade.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western World. It belongs to the low-grade non-Hodgkin lymphomas and is characterized by clonal reproduction of mature small-cell non-functional B-lymphocytes. CLL affects men somewhat more often than women and the average age at onset is over 50 years. In addition to regional lymph node swelling, typical symptoms include hepatosplenomegaly, leukocytosis and skin disorders such as eczema and pruritus. Manifestations in the oropharynx or hypopharynx are rare but should be kept in mind in the differential diagnosis.

Entities:  

Mesh:

Year:  2012        PMID: 21735280     DOI: 10.1007/s00106-011-2340-x

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  6 in total

Review 1.  [Chronic lymphocytic leukemia. 1. Diagnosis].

Authors:  M Hallek; B Schmitt; B Emmerich; H Stein
Journal:  Dtsch Med Wochenschr       Date:  2001-06-08       Impact factor: 0.628

Review 2.  [Chronic lymphocytic leukemia. 2. Therapy].

Authors:  M Hallek; B Schmitt; B Emmerich; H Stein
Journal:  Dtsch Med Wochenschr       Date:  2001-06-08       Impact factor: 0.628

Review 3.  Extranodal lymphomas of the head and neck.

Authors:  Francisco Vega; Pei Lin; L Jeffrey Medeiros
Journal:  Ann Diagn Pathol       Date:  2005-12       Impact factor: 2.090

Review 4.  [Malignant lymphoma in adults].

Authors:  M A Fridrik
Journal:  Dtsch Med Wochenschr       Date:  2008-10-01       Impact factor: 0.628

Review 5.  State-of-the-art treatment of chronic lymphocytic leukemia.

Authors:  Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

Review 6.  [Modern leukemia diagnosis in adults].

Authors:  B Heilmeier; K Spiekermann; S Bohlander; C Buske; M Feuring-Buske; S Schneider; W Hiddemann; J Braess
Journal:  Dtsch Med Wochenschr       Date:  2009-05-26       Impact factor: 0.628

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.